Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: myocardial PET imaging Clear all
Completed Phase 2 Interventional Results available

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

NCT04594941
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Ischemic Heart Disease
Interventions
Flurpiridaz (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Hialeah, Florida • Miami, Florida • North Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational

The Impact of Exercise-Induced Cardiac Remodeling on Myocardial Efficiency

NCT04580693
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
PET Scan
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 29, 2026, 5:15 AM EDT
Enrolling by invitation Phase 1 Interventional

PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis

NCT07771621
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
[18F]Fluselenamyl (FSA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational Results available

Sex and Obesity: Effects on Heart Failure Study

NCT00776035
View directory record Official record
Conditions
Obesity, Heart Failure
Interventions
PET (Positron Emission Tomography), Echocardiogram, ^15O-water, 1-^11C-palmitate, 1-^11C-glucose
Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational

Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)

NCT04343209
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Disease, Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions
Myocardial Perfusion Imaging Study, AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]
Diagnostic Test · Drug
Lead sponsor
Ionetix Corporation
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Miami, Florida • Miami Beach, Florida • Jenkintown, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 29, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations

NCT01262625
View directory record Official record
Conditions
Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent, Coronary Artery Disease
Interventions
CCTA, SPECT MPI/ICA
Device
Lead sponsor
American College of Radiology
Other
Eligibility
40 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Decatur, Georgia • Detroit, Michigan • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Terminated Early Phase 1 Interventional

Effect of Timi3 Ultrasound on Myocardial Blow Flow in the Hibernating Myocardium

NCT00655070
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Timi3 Transthoracic ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

NCT06510894
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Sotagliflozin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET

NCT00733460
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BFPET
Drug
Lead sponsor
Fluoropharma, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Imaging Coronary Microvascular Dysfunction (CMD) Study

NCT05634031
View directory record Official record
Conditions
Angina, Non-obstructive Coronary Artery Disease
Interventions
PET imaging, Coronary CT angiogram, Functional Angiography, Treadmill exercise stress study
Radiation · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group

NCT05280782
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ga-68 Galmydar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational

Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)

NCT00892307
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement
Radiation
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Right Ventricular Metabolism in Pulmonary Arterial Hypertension

NCT02763735
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Healthy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

NCT01919450
View directory record Official record
Conditions
Myocardial Blood Flow Reserve
Interventions
Regadenoson, Rubidium-82
Drug · Radiation
Lead sponsor
Timothy M. Bateman, MD
Industry
Eligibility
40 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Electromechanical Mapping to Evaluate Heart Muscle

NCT00001895
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
FDG, NH(3)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

18F-mFBG Imaging for Myocardial Sympathetic Innervation

NCT06965621
View directory record Official record
Conditions
Heart Failure, Ischemic Cardiomyopathy, ICD Patients
Interventions
18F-metaFluorobenzylguanidine, Rubidium-82
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling

NCT00603720
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
L-NAME, L-Arginine, Phenylephrine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

NCT05583721
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
[13N]NH3, Lexiscan, Positron emission tomography
Drug · Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed No phase listed Observational

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

NCT03535987
View directory record Official record
Conditions
Prostate Cancer
Interventions
myocardial PET imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
51 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.

NCT01066637
View directory record Official record
Conditions
Patients With Post Orthotopic Heart Transplantation Status
Interventions
[18F](+/-)NOS
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 29, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

18F-mFBG Cardiac Uptake With Lewy Body Dementia

NCT07176286
View directory record Official record
Conditions
Parkinson Disease (PD), Lewy Body Dementia (LBD)
Interventions
18F-MFBG
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 29, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

NCT03048097
View directory record Official record
Conditions
Sarcoidosis
Interventions
Fluorodeoxyglucose, Rubidium, FDG-PET/CT with Rb82 Myocardial Perfusion Imaging
Drug · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Sep 29, 2026, 5:15 AM EDT